Meropenem and piperacillin/tazobactam prescribing in critically ill patients : does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? by Carlier, Mieke et al.
This Provisional PDF corresponds to the article as it appeared upon acceptance. Copyedited and
fully formatted PDF and full text (HTML) versions will be made available soon.
Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does
augmented renal clearance affect pharmacokinetic/pharmacodynamic target
attainment when extended infusions are used?
Critical Care 2013, 17:R84 doi:10.1186/cc12705
Mieke Carlier (mieke.carlier@ugent.be)
Sofie Carrette (sofie.carrette@ugent.be)
Jason A Roberts (j.roberts2@uq.edu.au)
Veronique Stove (veronique.stove@ugent.be)
Alain G Verstraete (alain.verstraete@ugent.be)
Eric Hoste (eric.hoste@ugent.be)
Johan Decruyenaere (johan.decruyenaere@ugent.be)
Pieter Depuydt (pieter.depuydt@ugent.be)
Jeffrey Lipman (j.lipman@uq.edu.au)
Steven C Wallis (s.wallis@uq.edu.au)
Jan J De Waele (jan.dewaele@ugent.be)
ISSN 1364-8535
Article type Research
Submission date 8 January 2013
Acceptance date 16 April 2013
Publication date 3 May 2013
Article URL http://ccforum.com/content/17/3/R84
This peer-reviewed article can be downloaded, printed and distributed freely for any purposes (see
copyright notice below).
Articles in Critical Care are listed in PubMed and archived at PubMed Central.
For information about publishing your research in Critical Care go to
http://ccforum.com/authors/instructions/
Critical Care
© 2013 Carlier et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented 
renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended 
infusions are used? 
 
Mieke Carlier1,2, Sofie Carrette2, Jason A Roberts3, Veronique Stove4, Alain Verstraete1,5, Eric Hoste2, 
Johan Decruyenaere2, Pieter Depuydt2, Jeffrey Lipman3, Steven C Wallis3, Jan J De Waele2* 
 
1Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 
185, Ghent, 9000, Belgium. 2Department of Critical Care Medicine, Ghent University, De Pintelaan 
185, Ghent, 9000, Belgium. 3Burns Trauma and Critical Care Research Centre, The University of 
Queensland, Brisbane, Australia, Royal Brisbane and Women’s Hospital, Herston, QLD 4029, 
Australia. 4Department of Laboratory Medicine, Ghent University Hospital, De Pintelaan 185, Ghent, 
9000, Belgium. 5Department of laboratory medicine, Ghent University Hospital, De Pintelaan 185, 
Ghent, 9000, Belgium.  
 
*Corresponding author: Jan.DeWaele@ugent.be 
Abstract 
Introduction: Correct antibiotic dosing remains a challenge for the clinician. The aim of this study 
was to assess the influence of augmented renal clearance on pharmacokinetic/pharmacodynamic 
target attainment in critically ill patients receiving meropenem or piperacillin/tazobactam, 
administered as an extended infusion. 
Methods : This was a prospective, observational, pharmacokinetic study executed at the medical 
and surgical intensive care unit at a large academic medical center. Elegible patients were adult 
patients without renal dysfunction receiving meropenem or piperacillin/tazobactam as an extended 
infusion. Serial blood samples were collected to describe the antibiotic pharmacokinetics. Urine 
samples were taken from a 24-hour collection to measure creatinine clearance. Relevant data were 
drawn from the electronic patient file and the intensive care information system. 
Results: We obtained data from 61 patients and observed extensive pharmacokinetic variability. 
Forty-eight percent of the patients did not achieve the desired pharmacokinetic/pharmacodynamic 
target (100 % fT>MIC), of which almost 80 % had a measured creatinine clearance > 130 mL/min. 
Multivariate logistic regression demonstrated that high creatinine clearance was an independent 
predictor of not achieving the pharmacokinetic/pharmacodynamic target. Seven out of nineteen 
patients (37 %) displaying a creatinine clearance > 130 ml/min did not achieve the minimum 
pharmacokinetic/pharmacodynamic target of 50 % fT>MIC.  
Conclusions: In this large patient cohort, we observed significant variability in 
pharmacokinetic/pharmacodynamic target attainment in critically ill patients. A large proportion of 
the patients without renal dysfunction, most of whom displayed a creatinine clearance > 130 
mL/min, did not achieve the desired pharmacokinetic/pharmacodynamic target, even with the use 
of alternative administration methods. Consequently, these patients may be at risk for treatment 
failure without dose up-titration. 
Introduction 
Infection is a well recognized but persisting problem in critical care medicine. Sepsis alone is the 
leading cause of mortality in non-cardiac intensive care units, with up to 30 % of patients dying 
within one month of diagnosis [1, 2]. Adequate antibiotic therapy is one of the mainstays in 
treatment, with the emphasis on timely administration and appropriateness of the spectrum [3]. 
Optimizing antibiotic exposure is highly important as well, however, this is proving to be a greater 
challenge with recent data showing that antibiotic concentrations in critically ill patients are highly 
variable, unpredictable and commonly sub-optimal [4-7].  
Antibiotic dosing regimens are usually determined in healthy adults with normal physiology 
or non-critically ill hospitalized patients. Both the volume of distribution and clearance are the key 
determinants of the pharmacokinetics of a drug. Unfortunately, pathophysiological changes in 
critically ill patients have profound effect on both [8].  
One of these pathophysiological changes is the development of augmented renal clearance 
(ARC). This is a phenomenon in which renal elimination of circulating molecules – including 
antibiotics - is enhanced. This, in turn, may lead to sub therapeutic concentrations of time-
dependent antibiotics such as β-lactam antibiotics, potentially causing therapeutic failure and 
selection of antibiotic-resistant pathogens. Critically ill patients are at risk for ARC, because of their 
pathophysiological disturbances, as well as the clinical interventions administered [9, 10]. The 
incidence of ARC in critically ill patients is high and varies between 30 and 85 % depending on the 
studied population and the definition of ARC [11-13].  
One study has demonstrated the relationship between renal clearance and low antibiotic 
concentrations [14], but the relationship between renal clearance and β-lactam 
pharmacokinetic/pharmacodynamic characteristics has not been evaluated in a large cohort of 
patients. However, various pharmacokinetic modeling and simulation studies have suggested that 
using extended infusions will prevent low antibiotic exposure. However, this has never been tested 
in a large cohort of relevant patients with ARC. Therefore, the aim of this study was to assess the 
influence of renal clearance on pharmacokinetic/pharmacodynamic (PK/PD) target attainment when 
the antibiotic was administered as an extended infusion. Both the minimum target (50 % fT>MIC), as 
well as the target of 100 % fT>MIC which is considered to have higher bactericidal activity [15] were 
calculated. Notably this study enrolled patients without renal dysfunction, defined as an estimated 
glomerular filtration rate (eGFR) assessed by the MDRD equation of <80mL/min.  
 
Materials and methods 
Inclusion and exclusion criteria 
The data used for this analysis were collected in two separate studies performed in the medical and 
surgical ICU of Ghent University Hospital, a tertiary care hospital with a total of 50 adult ICU beds. 
Both studies were approved by the Ethics Committee of the Ghent University Hospital (study 1: 
registration number 2009/543, study 2: 2010/814). Written informed consent was obtained from 
the patient or his/her legal representative. 
Adult patients receiving either meropenem (Meronem®, AstraZeneca) or 
piperacillin/tazobactam (Tazocin®, Pfizer) were included if they did not meet exclusion criteria which 
included renal dysfunction (defined as an estimated glomerular filtration rate (eGFR) assessed by the 
MDRD equation of <80mL/min/1.73 m²), absence of an arterial catheter or absence of informed 
consent. 
Antibiotic administration 
Patients received a loading dose (1g meropenem or 4.5 g piperacillin/tazobactam) administered over 
30 minutes, followed immediately by the first extended infusion dose of either antibiotic (1g 
meropenem or 4.5 g piperacillin/tazobactam) every 6h for piperacillin/tazobactam and every 8 hours 
for meropenem. Extended infusion doses were administered over 3 hours using a syringe pump via a 
central venous catheter. 
Sampling and β-lactam assay 
The sampling strategy and β-lactam assay used was different in the studies that contributed patients 
for this analysis. Twenty patients were included in the first study, and forty-one in the second. 
Study 1 (20 patients) 
Eight serial plasma concentrations were obtained from each patient between 24-48 hours after the 
initiation of therapy at baseline and after 1, 1.5, 3, 3.5, 4, 6 and 8 hours for meropenem; at baseline 
and after 1, 1.5, 3, 3.5, 4, 5 and 6 hours for piperacillin. For each sample, 5mL of blood was collected 
in heparin anticoagulant tubes without separator gel, via the arterial catheter. Specimens were 
centrifuged at 3000 rpm for 10 min within 30 minutes of sampling, and then frozen at minus 80°C. 
They were shipped to the Burns, Trauma & Critical Care Research Centre of the University of 
Queensland, Australia for analysis by a specialized carrier. 
The samples were analysed at the Burns Trauma and Critical Care Research Centre, 
University of Queensland. The plasma concentrations of meropenem and piperacillin were 
determined by validated high performance liquid chromatography (HPLC) methods based on a 
published procedure that has been optimized for each drug [16]. Sample preparation was by protein 
precipitation with acetonitrile and a wash step with dichloromethane. Separations were performed 
on a Waters X-bridge C18 column (2.1 x 30 mm, 2.5 µm) with an acetonitrile: phosphate buffer 
mobile phase (pH 2.5 for meropenem, pH 3 for piperacillin). Detection was by UV at 304 nm 
(meropenem) or 210 nm (piperacillin). The meropenem assay was linear from 0.2 to 100 mg/L with 
an imprecision and inaccuracy <7% at high, medium and low concentrations. The piperacillin assay 
was linear from 0.5 to 500 mg/L with an imprecision and inaccuracy <10% at high, medium and low 
concentrations. Observed concentrations were corrected for protein binding (piperacillin 30%; 
meropenem 2%). 
Study 2 (41 patients) 
Two plasma samples were obtained per patient (mid-dose and trough), after administration of at 
least 3 doses, to ensure steady-state. For each sample, 5 mL of blood was collected in heparin-
anticoagulant tubes without separator gel, via the arterial catheter. The samples were then sent to 
the core laboratory of the Dept of Laboratory Medicine at the Ghent University Hospital, where they 
were centrifuged and frozen immediately upon arrival at minus 20°C and were analyzed on the same 
day. 
These samples were analysed at the toxicology laboratory of the Dept of Laboratory 
Medicine at the Ghent University hospital. The plasma concentrations of meropenem and 
piperacillin were determined by validated ultra high performance liquid chromatography coupled to 
tandem mass spectrometry (UPLC-MS/MS). Samples were deproteinized using acetonitrile. After 
centrifugation, a portion of the supernatant was diluted and injected on a Waters BEH C18 column 
(1.7 µm, 100 mm x 2.1 mm) kept at 50 °C and a gradient elution of water and acetonitrile, both 
containing 0.1 % formic acid. Compounds were detected with a Waters Acquity TQD mass 
spectrometer operating in positive electrospray ionization using a compound specific MRM method. 
The assay was linear from 2 to 80 mg/L for meropenem, and from 4 to 250 mg/L for piperacillin with 
an imprecision and inaccuracy < 15 % at high, medium and low concentrations. Observed 
concentrations were corrected for protein binding (piperacillin 30%; meropenem 2%).  
It should be highlighted that the samples in Study 1 and Study 2 were analysed using 
different assays in two different laboratories. Although a formal inter laboratory validation was not 
undertaken, both methods have been independently validated according to FDA guidelines. 
Furthermore, both laboratories monitor the quality of their analysis by using internal quality controls 
at 3 levels.  
Pharmacodynamic analysis 
Depending on the study and number of samples available, different methods were used to calculate 
the fT>MIC. When enough samples were available, the fT>MIC was calculated by observing the time 
during the dosing interval that the log-linear least squares regression analysis intersected the target 
MICs for Pseudomonas aeruginosa (16 mg/L for piperacillin and 2 mg/L for meropenem based on 
EUCAST breakpoints [17]. 
In the case when only two concentrations were available per patient, another approach was 
used. One concentration (C1) was taken halfway through the dosing interval, the second sample was 
a trough concentration (C2). Using these two concentrations, it is possible to calculate the 
elimination constant (equation 1).  
Equation 1 : C2 = C1 - e
k . t 
Assuming one compartmental first order kinetics, this is sufficient to calculate the time 
within the dosing interval where the concentration reaches or drops beneath a certain threshold. In 
order to investigate if these two approaches are comparable, the fT>MIC for the samples from the first 
study was calculated using the pharmacodynamic analysis used for the second study. This was 
performed for validation purpose only and was not used for the analyses. 
Measurement of creatinine clearance and calculation of estimates 
To calculate a reliable creatinine clearance, urine samples were taken from a 24-hour collection. 
Creatinine was measured in both serum/plasma and urine using the rate blanked, compensated and 
uncompensated Jaffe technique, respectively (Modular P and Cobas 6000, Roche Diagnostics GmbH, 
Mannheim, Germany). The creatinine clearance was calculated as follows : 
24 hour creatinine clearance = Uv x Ucr/( 1440 x Scr ), where Uv is the urinary volume (mL), Ucr the 
urinary creatinine concentration (µmol/L) and Scr the serum creatinine concentration (µmol/L).For 
assessment of ARC a cut-off of creatinine clearance ≥ 130 mL/min was used [14]. 
Statistical analysis 
The statistical analysis was performed using the statistical software package IBM-SPSS statistics 
version 20.0 (IBM Corp, New York USA). Data are expressed as median values with interquartile 
ranges (IQR) for continuous variables, numbers and percentages for categorical variables. In order to 
identify important covariates, multivariate logistic regression analyses (single step, forced entry) 
were conducted with target attainment 100 % fT>MIC and target attainment 50 % fT>MIC as dependent 
variable using the variables which gave a p-value of <0.10 in the univariate analysis. In the case of 
covariates which were closely related (such as weight, height and BMI), the one with the most 
significant p-value was chosen. Goodness of fit was assessed by the Hosmer-Lemeshow statistic. A 
receiver operator characteristic (ROC) curve was constructed to examine the sensitivity and 
specificity.  
All tests were two-tailed, and p<0.05 was considered statistically significant.  
 
Results 
Patients 
Sixty-one patients were included in the analysis. Patient characteristics on the day of study, and the 
comparison between the patients who did and did not reach the PK/PD target of both 100% fT>MIC 
and 50%fT>MIC are shown in Table 1. The median (IQR) creatinine clearance from all patients included 
in the study was 125 (93-173) mL/min ranging from 55 to 310 mL/min.  
Validation of the pharmacodynamic analyses 
It was found that the results for both methods used for determination of fT>MIC were comparable. 
Creatinine clearance and PK target attainment 
Sixty-one patients were included in the study. One patient was excluded from the analyses since no 
urine was collected, as a result of which the creatinine clearance could not be calculated. Six patients 
treated with meropenem had a trough concentration which was lower than the lower limit of 
quantification (2 mg/L), which is also the breakpoint MIC of Pseudomonas aeruginosa. This implies 
that these patients did not reach the desired target of 100 % fT>MIC, but the exact % fT>MIC could not 
be calculated, as this is not possible using only one sample. Two patients treated with 
piperacillin/tazobactam could also not be used for this analysis, because only the trough 
concentration was available, which is not enough to calculate the exact % fT>MIC . These eight 
patients were included in the analysis using the PK/PD target of 100 % fT>MIC, but could not be 
entered in the analysis using the PK/PD target of 50 % fT>MIC. 
Target 100 % fT>MIC 
Only 33 out of 60 patients (55%), for whom both creatinine clearance and trough concentrations 
were available, reached the PK/PD target of 100% fT>MIC. Patients who did not attain the predefined 
PK target (100%fT>MIC) were younger, had a higher creatinine clearance and a higher weight (Table 
1). Twenty-nine patients (48 %) had ARC, of which 22 (76 %) did not reach the PK target of 
100%fT>MIC. 
Figure 1 illustrates the fT>MIC for the patients with and without ARC. The mean fT>MIC in 
patients with and without ARC is shown in Figure 2 and was 61% vs. 94% in patients with and 
without ARC respectively (p<0.001). 
The results of the multivariate logistic regression are shown in Table 2. As the antibiotic 
administered was not significantly different between the groups who did and did not achieve the 
PK/PD target, this was not included in the multivariate analysis (p=0.264). Contrary to creatinine 
clearance and weight, age was not found to be significant in the multivariate analysis. The area 
under the ROC-curve was 0.86 (Figure 3a), with a sensitivity of 81% and a specificity of 81% for 
predicting target attainment at 50 % probability. 
As an illustration of the impact of an increase in creatinine clearance, the probability of 
achieving the PK/PD target of 100% fT>MIC was plotted according to the creatinine clearance using 
the logistic model for a patient aged 55 years, weighing 75 kg (Figure 4).  
Target 50 % fT>MIC 
Using the data from these 52 patients for whom both creatinine clearance and fT>MIC were available, 
we found that out of 19 patients displaying ARC, 7 (37 %) did not achieve the lower PK/PD target of 
50 % fT>MIC(p = 0.002) (Table 1) 
The results of the multivariate logistic regression analysis are shown in Table 3. As the 
antibiotic administered was not significantly different between the groups who did and did not 
achieve the PK/PD target, this was not included in the multivariate analysis (p=0.515). The area 
under the ROC- curve was 0.99, with a sensitivity of 95 % and a specificity of 100% for predicting 
target attainment at 50 % probability (Figure 3b). Only creatinine clearance was found to be 
significant in the multivariate analysis. 
 
Discussion 
In this large observational PK study, using clinical data from 61 critically ill patients with normal to 
increased renal function treated with meropenem or piperacillin/tazobactam, we found that ARC 
was associated with a higher risk of not achieving different PK/PD-targets in critically ill patients, 
even when administering these drugs by extended infusion. This calls into question the present 
approach to antibiotic dosing in these patients and supports use of more aggressive dosing 
strategies to minimize the likelihood of clinical failure. 
In patients with apparent normal renal function, the relationship between creatinine 
clearance and low target attainment may not come as a surprise as previous studies have already 
demonstrated the correlation between creatinine clearance and clearance of β-lactam antibiotics 
[18-26]. However, to the best of our knowledge, this study is the first to report the association 
between creatinine clearance and the lack of attainment of different PK/PD targets including the 
lower target of 50 % fT>MIC in patients with apparent normal renal function receiving antibiotic 
therapy administered as an extended infusion. Using trough antibiotic concentrations, Udy et al have 
demonstrated the association between subtherapeutic β-lactam concentrations and creatinine 
clearance in select critically ill patients [14]. In the current study we could also investigate other 
targets as we were able to use data from the entire antibiotic infusion, including the lower PK-target 
of 50 % fT>MIC. We found that - even when the dose was administered as an extended infusion - up to 
37% of the patients with ARC did not achieve this minimum PK/PD target - and may thus be at risk 
for treatment failure.  
Controversy exists in contemporary literature which PK target should be aimed for in 
critically ill patients, as it is not clear which PK/PD target is associated with highest probability of 
reaching clinical cure. Studies have shown that - depending on the antibiotic - 40 to 70% fT>MIC is 
necessary to treat infections [27]. However, recent research has shown that achieving higher targets 
may be associated with a higher probability of reaching clinical cure. In order to maximize the effect 
of β-lactam antibiotics, it may therefore be necessary to increase the fT>MIC to 100 % or even 
maintaining the concentration four to five times the MIC for the entire dosage duration [28-30]. 
Nevertheless, irrespective of the PK/PD target considered relevant, increasing creatinine clearance is 
associated with lower target attainments.  
Although ARC is a relatively new concept in intensive care medicine, its relevance should not 
be underestimated. The incidence in critically ill patients is high [11-13]. Implications for therapy 
with renally excreted drugs are considerable. Case reports have shown that some patients require 
up to 6, 8 or even 12 g meropenem per day to reach adequate serum concentrations [31, 32]. The 
effects of renal clearance are important not only for β-lactam antibiotics, but have also already been 
described for other antibiotics, such as vancomycin [14, 33].  
This study has a number of limitations. First of all, this study did not look at clinical outcomes 
as the data were drawn from PK studies. Logically, clinical cure and mortality should be investigated 
in future validation studies of altered antibiotic dosing, although these studies should be even larger 
than the present study. Secondly, we have described renal function at inclusion using the MDRD 
which has been shown to underpredict glomerular filtration rate in some critically ill patients [34, 
35]. Moreover this study was only a snapshot, and might not be representative for the entire course 
of treatment as creatinine clearance varies in the course of the disease. Also, this study is a single-
center study, which only included patients with apparent normal renal function, which limits 
extrapolation of these finding to all ICU patients. Finally, we have measured total drug 
concentrations with correction for protein binding based on literature. This is an oversimplification, 
but our data show that this approach is acceptable for these two antibiotics, although is not for 
more highly protein bound drugs.  
The findings from this study suggest that an even more sophisticated method of 
optimization may be necessary in selected patients - patient-tailored antibiotic therapy – which is 
the adaptation of antibiotic therapy to the need of the individual patient in order to maximize 
efficacy and minimize toxicity through therapeutic drug monitoring and dose adaptation. 
Unfortunately, TDM of β-lactam antibiotics is currently challenging with long turn-around times, 
expensive equipment, logistical problems related to the instability of the antibiotics in the samples 
and the need for well-trained personnel. Efforts to overcome these limitations, and clinical studies to 
assess utility in the clinical setting are urgently needed [36].  
 
Conclusions 
In conclusion, this study has demonstrated that in critical care patients receiving meropenem or 
piperacillin/tazobactam as an extended infusion, creatinine clearance is a key factor in the 
probability of PK/PD target attainment – irrespective if this is 50 or 100% fT>MIC. This study, which 
excluded patients with renal dysfunction, demonstrated that a specific subset of patients is at risk 
for PK/PD target non-attainment, more specifically those patients with increased creatinine 
clearances, even if the dose is administered as an extended infusion, which improves the fT>MIC. By 
means of multivariate logistic regression, it was found that a high creatinine clearance was an 
independent predictor of not achieving the PK/PD target, implying that without dose up-titration, 
these patients are at risk of treatment failure, even when extended infusions are used. 
 
Key messages 
• Antibiotic concentrations vary greatly in intensive care patients with normal kidney function. 
• The pharmacokinetic/pharmacodynamic target attainment is dependent on kidney function . 
• Patients with augmented renal clearance have a high probability of target non attainment, 
even with the use of an extended infusion strategy. 
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Figure 1. Histogram % fT>MIC for patients with and without augmented renal clearance (ARC). 
Figure 2. Mean % fT>MIC for patients with and without augmented renal clearance (ARC) with 95 % 
confidence interval. 
Figure 3. ROC curves of the binary logistic model. a : ROC curve for the logistic model with 
attainment of 100 % fT>MIC as dependent variable. b: ROC curve for the logistic model with 
attainment of 50 % fT>MIC as dependent variable. 
Figure 4. Predicted probability of 100 % fT>MIC target attainment in function of the creatinine 
clearance for a patient 55 years, weighing 75 kg. 
Table 1. Patient characteristics and comparison between patients who did and did not achieve the PK/PD target of 100 % fT>MIC and 50 % fT>MIC. . 
Variable All patients (n= 
60) 
PK/PD target (100 % 
fT>MIC) achieved 
(n= 33/60) (55%) 
PK/PD target (100 % 
fT>MIC) not achieved 
(n=27/60) (45 %) 
p-value PK/PD Target (50 % 
fT>MIC) achieved 
(n= 43/52) (86 %) 
PK/PD target (50 % 
fT>MIC) not achieved 
(n=7/52) (14 %) 
p-
value 
Male gender (n, %) 51 (85%) 28 (84%) 23 (85%) 0.721 36 (84 %) 7 (100%) 0.330 
Age (years) 56 (48-67) 61 (53–73) 51(30-60) 0.016 60 (52-72) 48 (25-67) 0.054 
Weight (kg) 78 (69-90) 75 (65-81) 83 (75-90) 0.014 75 (66-85) 85 (75-90) 0.041 
Height (m) 1.75 (1.70-1.80) 1.75 ( 1.67-1.79) 179 (1.72-1.80) 0.170 1.74 (1.68-1.80) 1.79 (1.75-1.80) 0.098 
BMI 25 (22-28) 24 (22-27) 25 (24-29) 0.084 24 (22-27) 25 (25-28) 0.188 
SOFA at the day of study 5 (3-7) 5 (2-8) 5 (3-6) 0.693 5 (3-8) 4 (2-6) 0.358 
Serum creatinine 
concentration (µmol/L) 
54 (43-75) 53 (44-79) 56 (41 - 64) 0.623 57 (44-76) 54 (38-59) 0.306 
Creatinine clearance 
(mL/min) 
 104 (87-123) 165 (138-208) <0.001 106 (91-143) 215 (190-246) <0.001 
Antibiotic used  
 Meropenem (n, %) 
 Piperacillin (n, %) 
 
17 (30%) 
43 (70%) 
 
7/17 (41%) 
25/43 (58%) 
 
10/17 (59%) 
18/43 (42%) 
0.24  
9/11 (82 %) 
33/41 (80 %) 
 
 2/11 (18 %) 
8/41 (20 %) 
0.515 
Data are reported as median (interquartile range). SOFA – Sequential Organ Failure Assessment. 
Table 2. Multivariate regression model with attainment of 100 % fT>MIC as dependent variable. 
 attainment of 100 % fT>MIC as dependent variable 
B p-value Exp(B) 95% C.I.for Exp(B) 
 Lower Upper 
Creatinine clearance (ml/min) -0.028 0.002 0.972 0.955 0.990 
Weight (kg) -0.040 0.114 0.961 0.915 1.010 
Age (years) 0.020 0.331 1.020 0.980 1.063 
Constant 5.788 0.033 326.34   
Table 3. Multivariate regression model with attainment of 50 % fT>MIC as dependent variable. 
 attainment of 50 % fT>MIC as dependent variable 
B p-value Exp(B) 95% C.I.for Exp(B) 
 Lower Upper 
Creatinine clearance (ml/min) -0.114 0.045 0.892 0.798 0.997 
Weight (kg) -0.035 0.616 0.965 0.841 1.108 
Age (years) 0.005 0.906 1.005 0.926 1.096 
Constant 24.07 0.07 2.8 x 1010   
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